CARDIOVASCULAR
hamburger

Between Two Ventricles™ is a cardiology podcast series brought to you by Abbott. Join us as our host, Phil Adamson MD, interviews leading specialists in the field of heart failure; highlighting the most up to date innovations, products and technologies for patient management and optimizing cardiac hemodynamics.

  • Listen, download and subscribe to our podcast channel

Episodes

Insights from the CLEAR-LVAD Study

Interview with Dr. Francis Pagani by Dr. Phil Adamson
July 8, 2021

With several implantable left ventricular assist devices (LVADs) being utilized in patients with advanced heart failure, the CLEAR-LVAD study aims to utilize real world data regarding survival outcomes and healthcare expenditures to provide comparisons across devices. Dr. Francis Pagani, Professor of Surgery and Director of the Heart Transplant Program and the Center for Circulatory Support at the University of Michigan Medical Center, will discuss the current state of LVAD therapy and how INTERMACS data can be utilized in clinical studies. Dr. Pagani will also review the findings of the CLEAR-LVAD study and how these results will impact the field of Mechanical Circulatory Support moving forward.

Between Two Ventricles

Attaining Health Equity – A Discussion on Racial Disparities in Heart Failure

Interview with Kelly McCants, M.D. by Dr. Phil Adamson
June 18, 2021

Kelly McCants, M.D., Medical Director of Advanced Heart Failure, and Executive Director of the Norton Healthcare Institute for Health Equity discusses how racial inequities in the management of heart failure patients can be identified and combated. Strategies for improving access to advanced therapies are also discussed.

Between Two Ventricles

The Power of Nutrition in Heart Failure Management

Interview with Dr. Peter McCullough by Dr. Phil Adamson
June 3, 2021

Heart failure is a major healthcare burden and there is a growing need to develop strategies to maintain health and sustain quality of life in people with heart failure. Often nutrition is an underused but powerful tool in managing heart failure. During this episode Dr. Peter McCullough, Vice Chief of Medicine at Baylor University Medical Center, will discuss the critical role nutrition interventions can play in improving outcomes for individuals with heart failure.

Between Two Ventricles

ECMO Therapy Troubleshooting

Interview with William Jakobleff, M.D. by Dr. Phil Adamson
May 19, 2021

William Jakobleff, M.D. shares his best practices for ECMO therapy troubleshooting and acute shock with the CentriMag™ Acute Circulatory Support System.

Between Two Ventricles

A Call to ACTION

Interview with Angela Lorts, MD, MBA by Dr. Phil Adamson
May 5, 2021

In this episode, Dr. Angela Lorts, Co-Executive Director of the ACTION Learning Network (Advanced Cardiac Therapies Improving Outcomes Network) and Director of the Ventricular Assist Device Program at Cincinnati Children’s Hospital Medical Center will discuss the importance of using a collaborative methodology with quality improvement methods to improve outcomes and define best practices. Dr. Lorts will also share how ACTION has been instrumental to the pediatric heart failure and congenital heart disease patient population.

Between Two Ventricles

COVID-19 and ECMO Therapy: Reflections One Year Into A Global Pandemic

Interview with Daniel Goldstein, M.D. by Dr. Phil Adamson
April 29, 2021

In this episode, Dr. Goldstein will reflect on how #COVID19 impacted advanced therapies and the future implications for #PatientCare.

Between Two Ventricles

Cracking the Case of the HFpEF Patient

Interview with Dr. Andrew J. Sauer by Dr. Phil Adamson
February 3, 2021

Patients with preserved heart failure are notoriously hard to diagnose and manage. In this episode, Dr. Andrew J. Sauer, Chief of Advanced Heart Failure Therapies Division and Associate Professor at the University of Kansas Health System, will discuss how the use of PA pressure monitoring with the CardioMEMS™ HF System can help optimize GDMT and reduce hospitalizations for this hard to manage patient population.

Between Two Ventricles

Advancing Heart Failure Care with LVAD Technology

Interview with Dr. Douglas Horstmanshof by Dr. Phil Adamson
January 13, 2021

In this episode we discuss the latest in MCS and when advanced therapies should be considered, with Dr. Douglas Horstmanshof, Co-Director, INTEGRIS Advanced Cardiac Care.

Between Two Ventricles

Between Two Ventricles Teaser

Extraordinary advances during the last few decades have allowed people to not only live longer lives, but fuller ones as well. This, however, has come with its own set of challenges as an aging population experiences a host of medical complications uncommon in younger cohorts; one of which is Heart Failure. To keep pace with its increasing prevalence, HF treatment methodology is continuously being optimized while technological innovations are constantly developed and improved upon, year after year.

Between Two Ventricles

This podcast represents the views of our guest speaker and do not necessarily represent the views of Abbott. For more information regarding the products featured during this podcast please refer to the approved US indication, important safety information and instructions for use.

For more educational content on Abbott’s life-changing medical device technologies and resources, please visit cardiovascular.abbott

MAT-2100894 v4.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.